MENU

NVAX Stock Novavax (NVAX, $18.17) RSI Indicator left the overbought zone on June 07, 2024

A.I.dvisor
at Tickeron.com
06/08/24
Loading...
NVAX - Novavax
RSI signal
Bearish Trend
Odds of DOWN Trend
Tickeron
RSI signal
Price: $18.17
Daily change: -$1.39 (-7.08%)
Daily volume: 21M
Capitalization: $2.7B
Industry: Biotechnology
This is a signal that NVAX's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options. A.I.dvisor looked back and found 29 similar cases where NVAX's RSI Indicator left the overbought zone, and in of them led to a successful outcome. Odds of Success:

NVAX in -13.82% downward trend, falling for three consecutive days on November 13, 2024

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where NVAX declined for three days, in of 324 cases, the price declined further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 16, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on NVAX as a result. In of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

NVAX moved below its 50-day moving average on October 16, 2024 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for NVAX crossed bearishly below the 50-day moving average on October 17, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

The Aroon Indicator for NVAX entered a downward trend on November 13, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

NVAX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. NVAX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (14.905). P/E Ratio (0.000) is within average values for comparable stocks, (98.894). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.944). NVAX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (1.795) is also within normal values, averaging (217.940).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NVAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

View a ticker or compare two or three
NVAX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a company which engages in development of novel recombinant vaccines

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
700 Quince Orchard Road
Phone
+1 240 268-2000
Employees
1534
Web
https://www.novavax.com